A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT ID: NCT06619587
Last Updated: 2026-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
410 participants
INTERVENTIONAL
2024-11-14
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01106599
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
NCT01090960
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
NCT00977067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I Arm A
Dose escalation and expansion arm
Phase I Arm A
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Phase I Arm B
Dose escalation and expansion arm
Phase I Arm B
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phase I Arm A
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Phase I Arm B
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm
Exclusion Criteria
* Active brain metastases
* Clinically significant cardiovascular dysfunction or liver disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC San Diego Moores Cancer Center
La Jolla, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Florida Cancer Specialist-Lake Mary
Lake Mary, Florida, United States
University of Illinois
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
START - Midwest - EDOS
Grand Rapids, Michigan, United States
Montefiore Einstein Cancer Center
The Bronx, New York, United States
Mary Crowley Medical Research Center
Dallas, Pennsylvania, United States
Abramson Cancer Center;Univ of Pennsylvania
Philadelphia, Pennsylvania, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Peter Maccallum Cancer Centre
Parkville, Victoria, Australia
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Sir Mortimer B Davis Jewish General Hospital
Montreal, Quebec, Canada
Rambam Health Care Campus
Haifa, , Israel
Hadassah University Hospital - Ein Kerem
Jerusalem, , Israel
The Chaim Sheba Medical Center
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, , Israel
National University Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
Seoul National University Bundang Hospital
Seongnam, , South Korea
Asan Medical Center.
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
Madrid, , Spain
Hospital Universitario Virgen de la Victoria
Málaga, , Spain
Hospital Universitario Virgen del Rocio - PPDS
Seville, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Western General Hospital;Edinburgh Cancer Center
Edinburgh, Midlothian, United Kingdom
NIHR UCLH Clinical Research Facility
London, , United Kingdom
The Christie
Manchester, , United Kingdom
Royal Marsden Hospital - Surrey
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: GO45416 https://forpatients.roche.com/
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GO45416
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.